A Novel CTLA-4 affinity peptide for cancer immunotherapy by increasing the integrin αvβ3 targeting

Abstract Immune checkpoint inhibitors (ICIs) are changing all aspects of malignant tumour therapy as an immunotherapy subverter in oncology. However, the current ICIs might induce systemic immune activation in other tissues and organs since they are not tumour-specific, causing the immune system to...

Full description

Bibliographic Details
Published in:Discover Oncology
Main Authors: Ying Zhou, Shuyi Song, Baomei Yuan, Yahong Wu, Yanfeng Gao, Guangming Wan, Guodong Li
Format: Article
Language:English
Published: Springer 2022-10-01
Subjects:
CTLA-4
Immune checkpoint inhibitors
Peripheral immunity
Peptide
Side effects
Online Access:https://doi.org/10.1007/s12672-022-00562-6

Internet

https://doi.org/10.1007/s12672-022-00562-6

Similar Items